NYSE · GSK
Healthcare · Drug Manufacturers - General
$50.82
Up+$0.55 (+1.09%)
Updated Aug 31, 2026, 7:34 AM
SID Score
6.7/10
Composite research score
Smart Money
56/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
GSK closed at $50.82 after 20 trading sessions, down 1.34% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $50.22 | $50.88 | $49.95 | $50.82 | 3.43M |
| Aug 27, 2026 | $50.945 | $51.03 | $50.165 | $50.27 | 2.47M |
| Aug 26, 2026 | $51.90 | $52.09 | $51.40 | $51.43 | 1.72M |
| Aug 25, 2026 | $51.57 | $52.21 | $51.51 | $52.07 | 2.7M |
| Aug 24, 2026 | $51.54 | $51.9491 | $51.40 | $51.78 | 2.89M |
| Aug 21, 2026 | $51.35 | $52.57 | $51.35 | $52.41 | 2.4M |
| Aug 20, 2026 | $52.57 | $52.63 | $51.86 | $51.96 | 3.6M |
| Aug 19, 2026 | $51.40 | $52.945 | $51.35 | $52.88 | 3.9M |
| Aug 18, 2026 | $50.76 | $51.3531 | $50.65 | $51.15 | 2.83M |
| Aug 17, 2026 | $49.93 | $50.365 | $49.875 | $50.28 | 2.81M |
| Aug 14, 2026 | $49.04 | $49.57 | $48.8603 | $49.52 | 3.72M |
| Aug 13, 2026 | $50.56 | $50.63 | $50.18 | $50.45 | 2.69M |
| Aug 12, 2026 | $50.11 | $50.47 | $49.8604 | $50.30 | 4.09M |
| Aug 11, 2026 | $51.95 | $52.355 | $50.90 | $50.90 | 2.92M |
| Aug 10, 2026 | $51.53 | $52.195 | $51.47 | $52.16 | 3.14M |
| Aug 7, 2026 | $52.71 | $53.085 | $52.42 | $52.96 | 2.52M |
| Aug 6, 2026 | $52.44 | $52.57 | $51.885 | $52.17 | 2.51M |
| Aug 5, 2026 | $52.06 | $52.12 | $51.36 | $51.46 | 2.48M |
| Aug 4, 2026 | $51.47 | $51.705 | $50.93 | $51.53 | 4.56M |
| Aug 3, 2026 | $52.10 | $52.27 | $51.045 | $51.51 | 4.53M |
The latest Smart Investors Daily articles mentioning GSK.
GSK research
Company profile and research snapshot.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 8, 2026 | Deutsche | Hold | — |
| May 28, 2026 | Jefferies | Buy | — |
| May 27, 2026 | Deutsche | Hold | — |
| May 6, 2026 | Deutsche | Hold | — |
| May 6, 2026 | Citigroup | Neutral | — |
No generated briefing is available yet.
SeekingAlpha · Aug 13, 2026
President Trump's executive order aimed at splitting the combined measles, mumps and rubella vaccine faces a major hurdle: none of the individual shots are currently licensed in the U.S.
Benzinga · Aug 11, 2026
During market turbulence, investors turn to dividend-yielding stocks. Benzinga provides analyst ratings for high-yield stocks in health care.
Benzinga · Aug 10, 2026
https://www.axios.com/2026/08/10/trump-order-split-up-mmr-vaccine
Benzinga · Jul 31, 2026
https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=2636#
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GSK.
